FDA Warns Consumers of Hidden Drug Ingredients in Certain Xcelerated Weight Loss Products

July 26, 2016

On Friday, July 22nd , the FDA published three public notifications warning consumers of hidden drug ingredients that are present in various Xcelerated Weight Loss products.  Two of the company’s products, Xcelerated Weight Loss Charged Up and Xcelerated Weight Loss Turbo Charge, have been found to contain sibutramine, a controlled substance, removed from the market for safety reasons in October 2010.  In its notice, the FDA states that these products pose a “threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.”  The Agency also notes the products could also have life-threatening interactions with other medications that consumers may be taking.

FDA’s third warning concerns Xcelerated Weight Loss Ultra Max, which has been found to contain phenolphthalein and sildenafil based on a laboratory analysis conducted by the FDA.  According to the Agency’s notice, studies involving phenolphthalein indicate that it presents a cancer-causing risk in previous studies.  Among its approved indications, Sildenafil is the active ingredient in Viagra, the FDA-approved drug indicated for the treatment of erectile dysfunction (ED).  In its public notification, FDA states that “this undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.”

FDA is advising consumers not to purchase or use these products, which are available online and in select retail stores.  In addition, FDA encourages patients and healthcare professionals to report any adverse events or side effects associated with the use of these products to its MedWatch Safety Information and Adverse Event Reporting Program.

Are you in the process of developing a dietary supplement? Do you have a supplement that you’re looking to verify is compliant with all FDA regulations? We can help you achieve a successful interaction with FDA.  To learn more about our services and how we can help you, contact us today.

General Regulatory Regulatory Sciences

April 3, 2013

Waivers for Carcinogenicity Studies? Not So Fast!

The recently published request for comments regarding the Proposed Change to Rodent Carcinogenicity Testing of Pharmaceuticals signals intent by regulatory agencies to alter what Sponsors consider in...

Read the Full Article
Agency Alerts General Regulatory

June 16, 2017

FDA to Host Public Workshop to Discuss the Impact of Abuse Deterrent Opioids

On Wednesday, June 14th, the FDA announced plans to host a public workshop regarding the impact of opioid formulations with abuse deterrent properties.  The workshop, entitled “Data and Methods for...

Read the Full Article
Quality & Compliance GMP

May 31, 2017

FDA Warns Drug Manufacturers of Recalls due to BCC Contamination

On Monday, May 22nd, the FDA issued a warning for drug manufacturers regarding the contamination risk posed by Burkholderia cepacia complex (BCC).  According to FDA’s warning, “BCC and other...

Read the Full Article